Jupiter Neurosciences Debuts Cellular Skin Health Supplement, Nugevia GLO

Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company, has launched Nugevia GLO-a “beauty-from-within” supplement designed to support radiant, resilient skin from the inside out by promoting cellular defense, collagen integrity, and hydration.

Nugevia GLO is a two-capsule-per-day regimen designed for optimal absorption and compliance. Key benefits include:

• Enhanced collagen synthesis and UV protection;
• Improved hydration and reduced pigmentation;
• Protection against oxidative stress and DNA damage; and
• Visible skin vitality through systemic cellular support.

“With Nugevia GLO, we’re taking our proprietary science to a broader audience,” said Christer Rosén, chairman and CEO of Jupiter Neurosciences. “GLO is not just another beauty supplement, it’s a clinically grounded formulation that enhances skin vitality by working at the cellular level. We’re unlocking a high-growth vertical in the $8 trillion longevity market while continuing to advance our pharmaceutical pipeline.”

Nugevia GLO leverages the synergy of JOTROL, Jupiter’s clinically validated resveratrol delivery technology, and NovaSOL Astaxanthin, a potent antioxidant known for its skin-enhancing properties. The product will be available via direct-to-consumer e-commerce platforms beginning Fall 2025.

JOTROL, which demonstrated a nine-fold increase in resveratrol bioavailability in Phase I trials, is central to Jupiter’s ongoing CNS clinical programs. When combined with astaxanthin — shown to improve skin elasticity, hydration, and pigmentation — the resulting formulation creates a solution for skin health and systemic rejuvenation.

High-Margin, High-Impact

The GLO product launch is part of Jupiter’s strategic shift into consumer wellness as a parallel growth engine to its therapeutic portfolio. Priced as a premium supplement, GLO represents a high-margin revenue stream with broad demographic appeal, including women over 35 seeking proactive skin and aging solutions.

Jupiter anticipates the Nugevia rollout, including GLO, PW R, and MND, will drive top-line growth and serve as a self-reinforcing capital engine. Revenues from GLO and the broader Nugevia line are expected to support clinical development, reduce capital dependency, and increase long-term shareholder value, the company said.